Stock PHRX PHARMADRUG INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Pharmadrug Inc.

Equities

PHRX

CA71716W2040

Market Closed - Canadian Securities Exchange
Other stock markets
 12:53:40 2024-05-15 EDT 		5-day change 1st Jan Change
0.035 CAD 0.00% Intraday chart for Pharmadrug Inc. +16.67% -36.36%
05-15 PharmaTher's Sairiyo Submits Clinical Trial Application in Australia For Phase 1 Study of Reformulated Cepharanthine MT
05-01 PharmaTher's Sairiyo Therapeutics Completes Regulatory Package For Phase 1 Study of Reformulated Cepharanthine in Australia MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PharmaTher's Sairiyo Submits Clinical Trial Application in Australia For Phase 1 Study of Reformulated Cepharanthine
MT
PharmaDrug's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
NE
PharmaDrug Provides Forward Plan to Move Its Patent Pending Process and Formulation of Pharmaceutical Grade Biosynthetic Cocaine Through Development into Commercialization
NE
PharmaDrug Announces Director Appointment and Resignation
NE
PharmaTher's Sairiyo Therapeutics Completes Regulatory Package For Phase 1 Study of Reformulated Cepharanthine in Australia
MT
PharmaDrug's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
NE
PharmaDrug's SecureDose Announces the Advancement of Process Development of Its Biosynthetic Formulation of Pharmaceutical Grade Cocaine
NE
PharmaTher Updated on its Priority Original Abbreviated New Drug Application for Ketamine
MT
Pharmadrug's SecureDose Announces Filing of US Provisional Patent for Manufacturing Method for Biosynthetic Pharmaceutical Grade Cocaine
CI
PharmaDrug's SecureDose Announces Filing of US Provisional Patent for Manufacturing Method for Biosynthetic Pharmaceutical Grade Cocaine
NE
PharmaDrug Inc Announces Board Changes
CI
PharmaDrug Appoints Current Board Member Dr. David Kideckel as Chairman
NE
PharmaTher Provides Update For PD-001
MT
PharmaDrug's Sairiyo Successfully Demonstrates Ability to Manufacture Cepharanthine (PD-001) for Human Clinical Studies
NE
Pharmadrug Inc. Announces Marketing and Distribution Services Agreement with Outside the Box Capital Inc
CI
PharmaDrug Inc. Engages Investor Relations and Marketing Service Providers
NE
PharmaDrug Inc. Announces Successful Closing of Non-Brokered Private Placement
NE
Pharmadrug Inc. announced that it has received CAD 0.326 million in funding
CI
PharmaDrug Inc. Announces Proposed Non-Brokered Private Placement
NE
Pharmadrug Inc. announced that it expects to receive CAD 0.326 million in funding
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PHRX Stock
  4. News Pharmadrug Inc.
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**BENEFIT NOW**0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW